John G. Van Putten
Groningen, GR, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study.
Journal: Clinical lung cancer
Published: December 16, 2024
Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy.
Journal: Acta oncologica (Stockholm, Sweden)
Published: November 04, 2024
External validation of NTCP-models for radiation pneumonitis in lung cancer patients treated with chemoradiotherapy.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: April 20, 2022
Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report.
Journal: Journal of medical case reports
Published: March 14, 2022
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 27, 2021
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC.
Journal: Targeted oncology
Published: February 03, 2021
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer.
Journal: Pharmacoepidemiology and drug safety
Published: April 02, 2020
Effects of crizotinib on creatinine clearance and renal hemodynamics.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 24, 2018
An instrument dedicated for modelling of pulmonary radiotherapy.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: December 03, 2014
Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer.
Journal: Radiation oncology (London, England)
Published: March 22, 2014
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2011
Showing 1-12 of 12
Last Updated: 09/26/2026